News
TherapeutAix Roundup: 2024
As another year comes to a close, we reflect on 12 months filled with innovation and collaboration at TherapeutAix. From kickstarting the year with strategic
Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma
A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update
The Evolving Landscape of IPF Drug Discovery and Development
Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite
TherapeutAix to attend ERS Congress 2024
TherapeutAix will be at the ERS Congress 2024 taking place in Vienna, Austria from 7-11th September. The Congress, hosted at RX Messe Wien, will bring
Fraunhofer 2024 Meeting
In late June, Simon Cruwys (Director, Pharmacology) attended and presented at the Fraunhofer Models of Lung Disease 2024 meeting in Hannover. This conference brought together
ECM2024 meeting
In late June, Darcey Black (Director, Translational) attended and presented at the ECM2024 meeting in Copenhagen. This conference brought together speakers and experts from industry
AI Target Identification: A novel approach to drive drug R&D in IPF?
Within the realm of lung diseases, developing new drugs to treat Idiopathic Pulmonary Fibrosis (IPF) remains a formidable challenge. Characterized by progressive scarring of